IONIS PHARMACEUTICALS INC 4

Director Ludwig Hantson received an equity compensation grant of 10,753 Ionis Pharmaceuticals Inc. stock options at a $75.13 exercise price.

On June 4, 2026, Ionis Pharmaceuticals Inc. director Ludwig Hantson received a grant of 10,753 non-qualified stock options with an exercise price of $75.13 per share under the company’s Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The options, which were not exercisable as of the grant date, will vest in three equal annual installments beginning June 4, 2027, and will be fully vested and exercisable by June 4, 2029, with an expiration date of June 4, 2036. Following this equity award, Hantson beneficially owns 10,753 shares (or equivalent option-based interest) of Ionis common stock on a direct basis.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000202

Alert Tier

5